Chapter: 1 INTRODUCTION

1.1 Key Benefits
1.2 Key Market Segments
1.3 Research Methodology

1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 Market beyond what to expect by 2025 ($Million)

2.1.1 Moderate growth scenario
2.1.2 Rapid growth scenario
2.1.3 Diminishing growth scenario

Chapter: 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Evolution of Erythropoietin drugs
3.3 Erythropoietin Omega and Delta: pruned R&D pipeline drugs
3.4 Ethical considerations of erythropoietin drugs
3.5 Key findings

3.5.1 Top Factors Impacting for Global Erythropoietin Drugs Market
3.5.2 Top Investment Pockets for Global Erythropoietin Drugs Market

3.6 Value Chain Analysis
3.7 Key market player positioning (2014)
3.8 Product positioning for patented products (2014)
3.9 Clinical trials for EPO drug in neural diseases and wound healing
3.10 Competitive Intelligence on top three leaders (Amgen, J&J and Roche)
3.11 Market share analysis, 2013
3.12 Market dynamics

3.12.1 Drivers

3.12.1.1 Increasing number cases: including cancer,HIV, kidney disease and anaemia
3.12.1.2 Growing trends of commercialization for erythropoietin biosimilars
3.12.1.3 Readily available reimbursements and favorable government regulations
3.12.1.4 Increasing level of awareness about the benefits of EPO therapeutics

3.12.2 Restraints

3.12.2.1 Unaffordability of therapeutics
3.12.2.2 Longer duration of treatments
3.12.2.3 Adverse amount of side effects

3.12.3 Opportunities

3.12.3.1 Commercialization of darbepotin alfa biosimilar
3.12.3.2 Achieving Economies of scale across developed region with biosimilar version of EPO

Chapter: 4 GLOBAL ERYTHROPOIETIN MARKET BY PRODUCTS

4.1 Epoetin-alfa

4.1.1 Historical Milestones
4.1.2 Commercial outlook
4.1.3 Approaches of clinical trials
4.1.4 Key market trends
4.1.5 Regulatory and reimbursement scenarios
4.1.6 Key growth factors and opportunities
4.1.7 Market size and forecast

4.2 Epoetin-beta

4.2.1 Historical Milestones
4.2.2 Approaches of clinical trials
4.2.3 Key market trends
4.2.4 Regulatory and reimbursement scenarios
4.2.5 Key growth factors and opportunities
4.2.6 Market size and forecast

4.3 Darbepoetin-alfa

4.3.1 Historical Milestones
4.3.2 Commercial outlook
4.3.3 Approaches of clinical trials
4.3.4 Key market trends
4.3.5 Regulatory and reimbursement scenarios
4.3.6 Key growth factors and opportunities
4.3.7 Market size and forecast

Chapter: 5 GLOBAL ERYTHROPOIETIN MARKET BY APPLICATIONS

5.1 Anemia (Cancer and HIV treatment)
5.2 Kidney Disorders (ESRD and Dialysis)
5.3 Others (Neural Disease and Wound healing)

Chapter: 6 GLOBAL ERYTHROPOIETIN MARKET BY GEOGRAPHY

6.1 North America

6.1.1 Key market trends
6.1.2 Reimbursement and regulations
6.1.3 Key growth factors and opportunities
6.1.4 Market size and forecast

6.2 Europe

6.2.1 Key market trends
6.2.2 Reimbursement and regulations
6.2.3 Key growth factors and opportunities
6.2.4 Market size and forecast

6.3 Asia-Pacific

6.3.1 Key market trends
6.3.2 Reimbursement and regulations
6.3.3 Key growth factors and opportunities
6.3.4 Market size and forecast

6.4 LAMEA

6.4.1 Key market trends
6.4.2 Reimbursement and regulations
6.4.3 Key growth factors and opportunities
6.4.4 Market size and forecast

Chapter: 7 COMPANY PROFILES

7.1 Amgen Inc.

7.1.1 Overview
7.1.2 Amgen Inc. snapshot
7.1.3 Financial performance
7.1.4 Operating Business Segment
7.1.5 SWOT analysis

7.2 Johnson and Johnson

7.2.1 Company overview
7.2.2 Johnson & Johnson snapshot
7.2.3 Operating Business Segment Overview
7.2.4 Financial performance
7.2.1 SWOT Analysis

7.3 Roche 

7.3.1 Company overview
7.3.2 Roche Diagnostics snapshot
7.3.3 Operating Business Segment Overview
7.3.4 Financial performance
7.3.5 SWOT analysis of Roche Diagnostics

7.4 Hospira

7.4.1 Company overview
7.4.2 Hospira snapshot
7.4.3 Operating Business Segment Overview
7.4.4 Financial performance
7.4.5 SWOT analysis of Hospira

7.5 LG Life Sciences Ltd.

7.5.1 Company overview
7.5.2 LG Life Sciences Ltd. snapshot
7.5.3 Operating Business Segment Overview
7.5.4 Financial performance
7.5.5 SWOT analysis of LG Life Sciences Ltd.

7.6 Biocon

7.6.1 Company overview
7.6.2 Biocon snapshot
7.6.3 Operating Business Segment Overview
7.6.4 Financial performance
7.6.5 SWOT analysis of Biocon

7.7 Intas Pharmaceuticals

7.7.1 Company overview
7.7.2 Intas Pharmaceuticals snapshot
7.7.3 Operating Business Segment Overview
7.7.4 Financial performance
7.7.5 SWOT analysis of Intas Pharmaceuticals

7.8 Teva Pharmaceutical Industries Ltd.

7.8.1 Company overview
7.8.2 Teva Pharmaceutical Industries Ltd. snapshot
7.8.3 Operating Business Segment Overview
7.8.4 Financial performance
7.8.5 SWOT analysis of Teva Pharmaceutical Industries Ltd.

7.9 Ranbaxy Laboratories Ltd.

7.9.1 Company overview
7.9.2 Ranbaxy Laboratories Ltd. snapshot
7.9.3 Operating Business Segment Overview
7.9.4 Financial performance
7.9.5 SWOT analysis of Ranbaxy Laboratories Ltd.

7.10 Celltrion, Inc

7.10.1 Company overview
7.10.2 Celltrion, Inc. snapshot
7.10.3 Operating Business Segment Overview
7.10.4 Financial performance
7.10.5 SWOT analysis of Celltrion, Inc.

LIST OF TABLES

TABLE 1  GLOBAL ERYTHROPOIETIN MODERATE GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 2  GLOBAL ERYTHROPOIETIN RAPID GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 3  GLOBAL ERYTHROPOIETIN DIMINISHING GROWTH SCENARIO BY GEOGRAPHY, 2020-2025 ($MILLION)
TABLE 4  ERYTHROPOIETIN DRUGS (COMPANIES, BRAND NAME, AND VARIANTS)
TABLE 5  CLINICAL TRIALS OF ERYTHROPOEITIN FOR NEURAL DISEASES AND WOUND HEALING
TABLE 6  COMPETITIVE INTELLIGENCE ON TOP THREE LEADERS IN ERYTHROPOIETIN MARKET
TABLE 7  BIOSIMILAR VERSION OF ERYTHROPOIETIN COMMERCIALIZED AND UNDER DEVELOPMENT
TABLE 8  CMS REIMBURSEMENT CODES FOR ERYTHROPOIETIN
TABLE 9  ORIGINATOR EPOTIN ALFA PRODUCTS AND THEIR REVENUES IN 2013
TABLE 10  BIOSIMILARS OF EPOETIN ALFA: APPROVED OR IN DEVELOPMENT PHASE
TABLE 11  CLINICAL TRIALS OF EPOETIN ALFA
TABLE 12  CMS POLICY CODES FOR EPOETIN ALFA
TABLE 13  EPOTIN BETA PRODUCTS AND THEIR REVENUES (2013)
TABLE 14  CLINICAL TRIALS FOR EPOETIN BETA
TABLE 15  CMS POLICY CODES FOR EPOETIN BETA
TABLE 16  BIOSIMILARS OF DARBEPOETIN ALFA
TABLE 17  CLINICAL TRIALS FOR DARBEPOETIN ALFA
TABLE 18  CMS POLICY CODES FOR DARBEPOETIN ALFA
TABLE 19  GLOBAL CANCER AND HIV INDUCED ANEMIA ERYTHROPOIETIN DRUGS APPLICATION MARKET BY GEOGRAPHY, 2013-2020, $MILLION
TABLE 20  DIALYSIS POPULATION GROWTH RATE IN 2013
TABLE 21  ESTIMATED (ESRD PATIENT) POPULATION BASE TAKING EPO THERAPY, 2013-2020, (THOUSAND)
TABLE 22  GLOBAL ESRD AND DIALYSIS INDUCED ANEMIA ERYTHROPOIETIN DRUGS APPLICATION MARKET BY GEOGRAPHY, 2013-2020, $MILLION
TABLE 23  GLOBAL NEURAL DISEASES AND WOUND HEALING INDUCED ANEMIA ERYTHROPOIETIN DRUG APPLICATION MARKET BY GEOGRAPHY, 2013-2020, $MILLION
TABLE 24  GLOBAL ERYTHROPOETIN MARKET BY GEOGRAPHY, 2013-2020 ($MILLION)
TABLE 25  SYNTHETIC ERYTHROPOIETIN MARKETED IN UNITED STATES
TABLE 26  REVISED USFDA GUIDELINES FOR THE DOSING OF ERYTHROPOIETIN STIMULATING AGENTS
TABLE 27  CMS POLICY DECISIONS FOR THE REIMBURSEMENT OF ERYTHROPOIETIN STIMULATING AGENTS
TABLE 28  NORTH AMERICA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013-2020 ($MILLION)
TABLE 29  EMA APPROVED ERYTHROPOIETIN (BIOSIMILARS AND INNOVATOR PRODUCTS) IN EUROPE
TABLE 30  EUROPE ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013-2020 ($MILLION)
TABLE 31  BIOSIMILARS MARKETED IN ASIA-PACIFIC
TABLE 32  ASIA-PACIFIC ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013-2020 ($MILLION)
TABLE 33  LAMEA ERYTHROPOETIN MARKET BY PRODUCT TYPES, 2013-2020 ($MILLION)
TABLE 34  AMGEN INC. SNAPSHOT
TABLE 35  AMGEN INC. OPERATING BUSINESS SEGMENT
TABLE 36  JOHNSON & JOHNSON SNAPSHOT
TABLE 37  JOHNSON AND JOHNSON OPERATING SEGEMENTS
TABLE 38  ROCHE SNAPSHOT
TABLE 39  ROCHE OPERATING SEGEMENTS
TABLE 40  HOSPIRA SNAPSHOT
TABLE 41  HOSPIRA OPERATING SEGEMENTS
TABLE 42  LG LIFE SCIENCES LTD. DIAGNOSTICS SNAPSHOT
TABLE 43  LG LIFE SCIENCES LTD. DIAGNOSTICS OPERATING SEGEMENTS
TABLE 44  BIOCON SNAPSHOT
TABLE 45  BIOCON OPERATING SEGEMENTS
TABLE 46  INTAS PHARMACEUTICALS SNAPSHOT
TABLE 47  INTAS PHARMACEUTICALS OPERATING SEGEMENTS
TABLE 48  TEVA PHARMACEUTICAL INDUSTRIES LTD. SNAPSHOT
TABLE 49  TEVA PHARMACEUTICAL INDUSTRIES LTD. OPERATING SEGEMENTS
TABLE 50  RANBAXY LABORATORIES LTD. SNAPSHOT
TABLE 51  RANBAXY LABORATORIES LTD. OPERATING SEGEMENTS
TABLE 52  CELLTRION, INC. SNAPSHOT
TABLE 53  CELLTRION, INC. OPERATING SEGEMENTS

LIST OF FIGURES

FIG. 1  IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN MODERATE GROWTH SCENARIO
FIG. 2  IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN RAPID GROWTH SCENARIO
FIG. 3  IMPACT ANALYSIS OF GLOBAL ERYTHROPOIETIN MARKET IN DIMINISHING GROWTH SCENARIO
FIG. 4  GLOBAL ERYTHROPOIETIN (EPO) DRUGS MARKET DEFINITION
FIG. 5  EVOLUTION OF ERYTHROPOIETIN DRUGS
FIG. 6  TOP IMPACTING FACTORS OF GLOBAL ERYTHROPOIETIN DRUGS MARKET (2013-2020)
FIG. 7  TOP INVESTMENT POCKETS FOR GLOBAL ERYTHROPOIETIN DRUGS MARKET
FIG. 8  ERYTHROPOIETIN (EPO) VALUE CHAIN BY APPLICATION
FIG. 9  MARKET PLAYER POSITIONING OF ERYTHROPOIETIN DRUGS MARKET, 2014, (MILLION)
FIG. 10  ERYTHROPOIETIN PATENTED PRODUCT POSITIONING (2014)
FIG. 11  MARKET SHARE ANALYSIS OF GLOBAL ERYTHROPOIETIN DRUGS MARKET (2013)
FIG. 12  REGIONAL SALES OF NEORECORMON AND MIRCERA IN 2013 ($ MILLION)
FIG. 13  FORECAST ADOPTION OF EPO THERAPY BY GEOGRAPHY, 2013-2020 (% RATE)
FIG. 14  FINANCIAL REVENUE OF AMGEN INC. BY GEOGRAPHY (2013)
FIG. 15  FINANCIAL REVENUE OF AMGEN INC. BY PRODUCT PORTFOLIO (2013)
FIG. 16  SWOT ANALYSIS OF AMGEN INC.
FIG. 17  FINANCIAL REVENUE OF JOHNSON & JOHNSON BY GEOGRAPHY (2013)
FIG. 18  FINANCIAL REVENUE OF JOHNSON & JOHNSON BY BUSINESS UNITS (2013)
FIG. 19  SWOT ANALYSIS OF JOHNSON & JOHNSON
FIG. 20  FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
FIG. 21  FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY BUSINESS UNITS (2013)
FIG. 22  SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIG. 23  FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
FIG. 24  FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY BUSINESS UNITS (2013)
FIG. 25  SWOT ANALYSIS OF ROCHE 
FIG. 26  SWOT ANALYSIS OF LG LIFE SCIENCES LTD.
FIG. 27  SWOT ANALYSIS OF HOSPIRA 
FIG. 28  SWOT ANALYSIS OF INTAS PHARMACEUTICALS
FIG. 29  SWOT ANALYSIS OF TEVA PHARMACEUTICAL INDUSTRIES LTD.
FIG. 30  SWOT ANALYSIS OF RANBAXY LABORATORIES LTD.
FIG. 31  SWOT ANALYSIS OF CELLTRION, INC.